WINTON GROUP Ltd Takes $1.12 Million Position in Theravance Biopharma, Inc. $TBPH

Key Points

• WINTON GROUP Ltd bought 76,542 shares of Theravance Biopharma (~$1.12 million), representing about 0.15% of the company at the end of the quarter.
• Institutional ownership is very high (≈99.10%), with major holders like Vanguard (2.21M shares, ~$32.3M) and Dimensional Fund Advisors (766,704 shares) increasing or holding sizable stakes.
• Analysts are mixed but the consensus is a Moderate Buy with a $22.60 target; TBPH trades around $13.81 (market cap ≈ $700M) and has a 52-week range of $7.90–$21.03.

WINTON GROUP Ltd purchased a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 76,542 shares of the biopharmaceutical company's stock, valued at approximately $1,118,000. WINTON GROUP Ltd owned approximately 0.15% of Theravance Biopharma at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Integrated Quantitative Investments LLC acquired a new stake in shares of Theravance Biopharma during the 3rd quarter worth about $368,000. Dimensional Fund Advisors LP increased its holdings in Theravance Biopharma by 6.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 766,704 shares of the biopharmaceutical company's stock valued at $11,193,000 after purchasing an additional 44,634 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Theravance Biopharma during the 3rd quarter valued at $387,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Theravance Biopharma in the 3rd quarter valued at about $4,536,000. Finally, Vanguard Group Inc. raised its stake in Theravance Biopharma by 2.5% during the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company's stock worth $32,289,000 after acquiring an additional 54,152 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TBPH. B. Riley Financial reiterated a "neutral" rating and set a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research report on Wednesday, March 4th. Oppenheimer lowered shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating in a research note on Thursday, March 5th. HC Wainwright upped their target price on Theravance Biopharma from $20.00 to $27.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Wall Street Zen cut shares of Theravance Biopharma from a "strong-buy" rating to a "buy" rating in a report on Saturday, January 3rd. Finally, BTIG Research reduced their price objective on shares of Theravance Biopharma from $40.00 to $21.00 and set a "buy" rating for the company in a research note on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Theravance Biopharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $22.60.

Theravance Biopharma Price Performance

Shares of TBPH stock opened at $13.81 on Thursday. The stock has a 50-day moving average of $18.66 and a 200-day moving average of $16.86. The stock has a market cap of $699.75 million, a PE ratio of 24.23 and a beta of 0.17. Theravance Biopharma, Inc. has a one year low of $7.90 and a one year high of $21.03.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.